Merus Net Income 2016-2021 | MRUS

Merus net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Merus Annual Net Income
(Millions of US $)
2020 $-86
2019 $-55
2018 $-28
2017 $-83
2016 $-52
2015 $-26
Merus Quarterly Net Income
(Millions of US $)
2021-09-30 $-15
2021-06-30 $-27
2021-03-31 $-10
2020-12-31 $-28
2020-09-30 $-23
2020-06-30 $-18
2020-03-31 $-17
2019-12-31 $-25
2019-09-30 $-9
2019-06-30 $-13
2019-03-31 $-7
2018-12-31 $-0
2018-09-30 $-12
2018-06-30 $-5
2018-03-31 $-10
2017-12-31 $-17
2017-09-30 $-18
2017-06-30 $-24
2017-03-31 $-23
2016-12-31 $-35
2016-09-30 $-6
2016-06-30 $-6
2016-03-31 $-6
2015-12-31 $-7
2015-09-30 $-7
2015-06-30 $-6
2015-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.105B $0.030B
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69